How can we recognize “disease modification” effects?

Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy

Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text

Life Sciences, Neurology, Neuroscience +17

Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families

Elizabeth H. Corder, Ann M. Saunders, Warren J. Strittmatter et al. · Science · 1993 · 9.5K citations

Life Sciences, Genetics, Neurology +17

Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease

Ann M. Saunders, Warren J. Strittmatter, D. E. Schmechel et al. · Neurology · 1993 · 3.8K citations · Full text

Life Sciences, Genetics, Neurology +17

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

S. Gilman, M. Köller, R. S. Black et al. · Neurology · 2005 · 1.3K citations

Medicine, Neurology, Neuroscience +17

Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly

Howard Aizenstein, Robert D. Nebes, Judith Saxton et al. · Archives of Neurology · 2008 · 1.1K citations

Medicine, Neurology, Neuroscience +17